Morris & Dickson announced it has completed its acquisition of Prodigy Health, a specialty pharmaceutical distribution and services company, in a deal the distributor positioned as an expansion of its specialty portfolio and its ability to serve alternative sites of care nationwide. The Shreveport, Louisiana-based company described the transaction as a way to broaden access to plasma-derived therapies while maintaining continuity, compliance, and uninterrupted service for healthcare providers.
The company framed the acquisition as a long-term investment in specialty distribution and the growing demand environment for specialty and plasma therapies. Morris & Dickson said Prodigy Health’s capabilities will strengthen support for hospitals, specialty pharmacies, clinics, infusion centers, and other care settings that rely on reliable ordering, fulfillment, and service levels as therapies become more complex and more sites of care options move outside traditional hospital settings.
Morris & Dickson also highlighted the manufacturer side of the equation, arguing that the combined platform creates a broader independent distribution channel with expanded reach and a compliance-first operating model. The company said the combination is designed to help manufacturers reach diverse sites of care while meeting expectations around regulatory integrity and service consistency.
As part of the close, Morris & Dickson said it will begin a phased integration process using a structured transition services model aligned with industry best practices and applicable regulatory requirements. The acquired business will operate as ProdigyMD, and Morris & Dickson said the approach is intended to preserve operational stability, allowing customers and manufacturers to access expanded capabilities without disruption.
For customers, the company said the near-term priority is continuity, including uninterrupted ordering, fulfillment, and support. Morris & Dickson said it plans to integrate Prodigy Health’s plasma and specialty tools and make those capabilities available across its broader customer base over time.
Morris & Dickson added that, effective immediately, Prodigy Health employees will join the Morris & Dickson organization. The company described Morris & Dickson as an independent full-line and specialty pharmaceutical distributor founded in 1841 and headquartered in Shreveport, serving health systems, independent pharmacies, clinics, infusion centers, and alternative care facilities nationwide. It described ProdigyMD as the successor to Prodigy Health, established in 2001 in Austin, Texas, focused on access to plasma-derived products and specialty pharmaceutical therapies while continuing Prodigy’s legacy as part of Morris & Dickson’s specialty distribution platform.
KEY QUOTES
“This transaction reflects our long-term commitment to specialty distribution and alternative sites of care. Our focus is on expanding access to critical therapies while preserving continuity for customers and operating with regulatory integrity that is consistent with our independent, customer-first values.”
Jody Hatcher, Chief Executive Officer, Morris & Dickson
“This is a meaningful step forward in our specialty strategy. By bringing Prodigy Health’s purpose-built plasma and specialty expertise into the Morris & Dickson family, we are strengthening our ability to support complex therapies while maintaining the service and compliance our customers expect. Our immediate focus is disciplined execution and personalized customer support.”
Layne Martin, Head of Specialty, Morris & Dickson
“By combining Morris & Dickson’s national reach with Prodigy Health’s specialty and plasma expertise, we are creating a reliable channel that helps manufacturers reach diverse sites of care while maintaining the service levels and regulatory integrity they expect.”
Jason Hanks, Chief Commercial Officer, Morris & Dickson
